Functional characterization of naturally occurring transglutaminase 2 mutants implicated in early-onset type 2 diabetes

Neil W Salter¹, Sudharsana R Ande²*, Hoa K Nguyen¹*, B L Grégoire Nyomba¹,2 and Suresh Mishra¹,2

Departments of ¹Physiology and ²Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

(Correspondence should be addressed to S Mishra who is now at Diabetes Research Group, University of Manitoba, 843 JBRC/715 McDermot Avenue, Winnipeg, Manitoba, Canada R3E 3P4; Email: mishra@cc.umanitoba.ca)

* (S R Ande and H K Nguyen contributed equally to this work)

Abstract

Transglutaminase 2 (TG2) is an enzyme with diverse biological functions. TG2 catalyzes transamidation reactions, has intrinsic kinase activity, and acts as a G-protein in intracellular signaling. TG2 (Tgm2)-null mice are glucose intolerant and have impaired glucose-stimulated insulin secretion (GSIS). Furthermore, three naturally occurring missense mutations in the human TGM2 gene, corresponding to amino acid substitutions of Met330Arg, Ile331Asn, and Asn333Ser in the TG2 protein, have been reported and found to be associated with early-onset type 2 diabetes. However, their effect on TG2 function is not fully understood. To determine this, we have reproduced naturally occurring mutations in TG2 using site-directed mutagenesis. Overexpression of Myc-TG2 mutants in INS-1E cells resulted in a reduction of GSIS in comparison with cells overexpressing wild-type Myc-TG2 (WT-TG2). The maximum reduction was found in cells overexpressing Ile331Asn-TG2 (32%) followed by Met330Arg-TG2 (20%), and the least in Asn333Ser-TG2 (7%).

Enzymatic analysis revealed that TG2 mutants have impaired transamidation and kinase activities in comparison with WT-TG2. GTP-binding assays showed that TG2 mutants also have altered GTP-binding ability, which is found to be modulated in response to glucose stimulation. Collectively, these data suggest that naturally occurring mutations in TG2 affect transamidation, kinase, and GTP-binding functions of TG2. While reduced insulin secretion, as a result of naturally occurring mutations in TG2, is due to the impairment of more than one biological function of TG2, it is the transamidation function that appears to be impaired during the first phase, whereas the GTP-binding function affects the second phase of insulin secretion.

Journal of Molecular Endocrinology (2012) 48, 203–216

Introduction

Transglutaminase 2 (TG2) is a multi-functional protein-modifying enzyme (EC 2.3.2.13) that has been mapped to the locus 20q12 on human chromosome 20 (Gentile et al. 1994). The locus 20q12 has been identified as a susceptibility locus for non-insulin-dependent type 2 diabetes in linkage studies and is believed to contain more than one susceptibility gene (Ji et al. 1997, Zouali et al. 1997, Ghosh et al. 1999). One such gene is hepatocyte nuclear factor 4α (HNF4A). Mutations in the HNF4A gene have been reported to be involved in young-onset type 2 diabetes (Johnson 2007). In addition to HNF4A, mutations in the TG2 (TGM2) gene have also been implicated in young-onset type 2 diabetes (Bernassola et al. 2002, Porzio et al. 2007). Three heterozygous missense mutations in the TG2 gene, which lead to amino acid changes in the TG2 protein at positions 330, 331, and 333 from methionine to arginine (Met330Arg), isoleucine to asparagine (Ile331Asn), and asparagine to serine (Asn333Ser) respectively, have been identified in patients with young-onset type 2 diabetes (Bernassola et al. 2002, Porzio et al. 2007). Furthermore, mice lacking TG2 (TG2−/−) are glucose intolerant and have impaired glucose-stimulated insulin secretion (GSIS) and exhibit a phenotype similar to maturity onset diabetes of the young (MODY), a group of autosomal dominant, single-gene disorders that cause diabetes in young adults or children (Bernassola et al. 2002). The genetic evidences together suggest an important physiological role for TG2 in pancreatic β-cell function, though the actual mechanism involved is not understood.

A well-known function of TG2 is calcium-dependent transamidation, which is also known as a ‘protein crosslinking’ function, due to the formation of a γ-glutamyl-ε-lysine bond between the side chain of lysine and glutamine residues of two protein molecules (Fesus & Piacentini 2002). Recently, serotonylation (covalent coupling of serotonin to protein) of small G-proteins in pancreatic β-cells mediated by the transamidation function of TG2 has been implicated
in GSIS (Paulmann et al. 2009). In this paper, the enzyme TG2 placed serotonin on glutamine residue(s) of small GTPases to form a glutamyl amide bond (serotonylation), resulting in the activation of G-proteins (Paulmann et al. 2009). Small GTPases have been known to be involved in insulin secretion from β-cells (Kajio et al. 2001, Kasai et al. 2005). For example, a small GTPase, Rab5a, has been shown to regulate replenishment of the readily releasable pool of β-granules at early stages of vesicle transport (Kajio et al. 2001). Furthermore, Rab27a has been reported to act directly in the targeting of β-granules from the resting pool to the readily releasable pool in the plasma membrane (Kasai et al. 2005).

In addition, we have reported that TG2 has intrinsic kinase activity and phosphorylates a number of proteins including insulin-like growth factor binding protein-3 (IGFBP3; Mishra & Murphy 2004, Mishra et al. 2006, 2007a,b). We have recently found that IGFBP3 has a role in insulin secretion (Nguyen et al. 2011). Moreover, we have shown that ATP and Ca2+ reciprocally regulate transamidation and kinase activities of TG2 (Mishra & Murphy 2004). ATP facilitates kinase activity and has an inhibitory effect on transamidation activity, whereas Ca2+ has an opposite effect (Mishra & Murphy 2004, Mishra et al. 2007a,b). Furthermore, TG2 binds to GTP and functions as a G-protein in cell signaling processes (Baek et al. 2007), and the GTP-binding and transamidation functions of TG2 are inversely associated with each other (Murthy et al. 2002, Begg et al. 2006). Although the transamidation catalytic triad (Cys277, His335, and Asp358) and putative GTP/ATP (169Gln-Gly-Ser-Ala-Lys173 and 586Arg-Asp-Leu-Tyr583) binding loops are located distantly from each other in the primary structure of TG2, they are very close to each other in the secondary structure, as revealed by the crystal structure of TG2 (Murthy et al. 2002, Begg et al. 2006). However, the functional consequences of naturally occurring TG2 mutations on TG2 enzymatic activities and on GTP-binding function have not been characterized yet. Although a role for the transamidation function of TG2 in GSIS has been proposed (Porzio et al. 2007), there is no unequivocal evidence to support this hypothesis. Moreover, the possibility of the involvement of TG2 functions other than the transamidation and kinase activities of TG2 in a mutually exclusive or in an inclusive manner. Moreover, it may also affect the GTP-binding ability of TG2 and its function as a G-protein. In this study, we investigated the functional impact of naturally occurring TG2 mutations on TG2 enzymatic activities as well as on the GTP-binding function and their relationship with GSIS in clonal INS-1E pancreatic β-cells.

Materials and methods

Reagents

Cell culture reagents were obtained from American Type Cell Collection (ATCC, Danvers, MA, USA), and heat-inactivated fetal bovine serum and anti-rabbit Alexa Fluor 488 from Invitrogen. Anti-Myc antibody was obtained from Cell Signaling Technology (Danvers, MA, USA), and anti-serotonin antibody and HRP-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology. ProFound c-Myc Tag IP/Co-IP Kit and 5-(biotinamido)pentylamine (BPNH2) were purchased from Pierce (Rockford, IL, USA) and Ultrasensitive Insulin ELISA kits (mouse and rat) were obtained from Chrystal Chem (Downers Grove, IL, USA). Enhanced chemiluminescence (ECL) reagents and sequencing grade trypsin were purchased from Promega. ATP- and GTP-agarose resins were obtained from Innova Biosciences (Cambridge, UK). Other reagents were purchased from Sigma–Aldrich or as otherwise stated.

Animals

TG2 knockout C57BL/6 mice were generously provided by Dr Nikolaos Frangogiannis (Baylor College of Medicine, Houston, TX, USA) with permission from Dr Gerry Melino (University of Leicester, UK). Wild-type (WT) and TG2+/− C57BL/6 mice were housed at the University of Manitoba Central Animal Care Facility. Mice were housed under controlled temperature (21 °C) and light conditions (12 h light:12 h darkness cycle) with ad libitum access to water and a standard diet. The experiments involving mice were performed as approved by the Animal Care Committee of the University of Manitoba.

Isolation of pancreatic islets

Islets were isolated by collagenase (Roche) digestion of the mouse pancreas as described (Lacy & Kostianovsky 1967). Once isolated, the islets were cultured in RPMI-1640 medium containing 11 mM glucose, 10% heat-inactivated fetal bovine serum, and 100 μg/ml penicillin–streptomycin for 24 h (Nguyen et al. 2011).

Batch incubations

Batches of four islets were pre-incubated in Krebs–Ringer bicarbonate (KRB) buffer solution (118 mM NaCl, 4.7 mM KCl, 1.9 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, and 25 mM NaHCO3 (equilibrated with 5% CO2–95% O2, pH 7.4, 0-2% BSA, and 10 mM HEPES) containing 3.3 mM glucose for 30 min. The islets were then incubated for 30 min in KRB buffer.
containing 16.7 mM glucose. The buffer samples were collected for the insulin assay by ELISA according to the manufacturer’s instructions.

**Cell culture**

The rat insulinoma cell line INS-1E was a generous gift from Dr Michael Wheeler (University of Toronto, Toronto, ON, Canada) with permission from Prof. Claes Wollheim (University of Geneva, Geneva Switzerland). INS-1E cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 10 mM HEPES, 1 mM sodium pyruvate, 50 μM β-mercaptoethanol, 100 μg/ml penicillin–streptomycin (Gauthier et al. 2009, Lee et al. 2010).

**TG2 constructs and cell transfections**

The pCMV6 vector containing the Myc-tagged human TG2 (Myc-TG2) clone was obtained from Origene Technologies (Rockville, MD, USA). Naturally occurring TG2 mutants and the transamidation-activity dead Cys277Ala-TG2 mutant (as a negative control for the transamidation function of TG2) were made using a site-directed mutagenesis kit (Ande et al. 2009a, b) using two complementary oligonucleotide primers containing the desired mutation and Myc-TG2 as the template. The primers used for generating various TG2 mutants are shown in Table 1. The parental strand was removed by DpnI digestion before transformation into Escherichia coli strain DH5α. Authenticity of all constructs was confirmed by DNA sequencing. Transfections with various constructs were performed using FuGENE HD transfection reagent (Roche) according to the manufacturer’s instructions (Ande et al. 2009a, b). A consistent transfection efficiency of 40–45% was obtained using 2 μg plasmid DNA/3 μl transfection reagent.

**Immunoprecipitation**

The ProFound c-Myc Tag IP/Co-IP Kit was used, according to the manufacturer’s instructions, to immunoprecipitate the Myc-tagged WT and TG2 mutants. For the samples to be used in kinase and transamidation activity assays, rather than subjecting to elution, the protein–bead complexes were resuspended in 50 mM Tris buffer (pH 7.4) to preserve enzyme activity.

**Western blotting**

Cells were rinsed in PBS and collected in lysis buffer (Sigma–Aldrich), containing protease inhibitor cocktail (Ande et al. 2009a, b). The samples were incubated on ice with intermittent vortexing for 30 min, followed by centrifugation at 13 000 g for 10 min. Protein concentrations of the supernatants were determined by the Bradford protein assay with BSA as the standard. SDS–PAGE sample buffer was added to the samples, and the samples were then boiled for 5 min. Proteins were resolved on 10–12% SDS–PAGE, according to target protein size, and transferred onto nitrocellulose membranes. The membranes were blocked in 5% milk for 1 h at room temperature and then incubated with primary antibodies for 1 h at room temperature or overnight at 4 °C. Membranes were washed three times with TBST wash buffer (10 mM Tris, 150 mM NaCl, 0·05% Tween 20, pH 8.0), and then incubated with either HRP-conjugated secondary antibodies or streptavidin-HRP conjugate for 1 h at room temperature. Membrane washing steps with TBST were repeated, followed by the addition of ECL reagent. Membranes were exposed to Kodak Biomax MR Film (Sigma) and protein bands were analyzed by densitometry using Scion Image software (Frederick, MD, USA).

**In vitro kinase assay**

An in vitro kinase assay was performed in kinase buffer (50 mM Tris–HCl, pH 7.5, 10 mM magnesium chloride, [γ-32P]ATP (25 μCi/ml)) for 30 min at 30 °C as described previously (Mishra & Murphy 2004, Mishra et al. 2006). The reaction was stopped by the addition of SDS–PAGE sample buffer and the samples were boiled for 5 min. The samples were resolved on SDS–PAGE,

| Primer sequences used to develop TG2 mutants by site-directed mutagenesis |
|-----------------------------------|-----------------------------------|
| **TG2 mutants**                  | **Primer sequences**              |
| Met330Arg                         | Forward: 5'-GTGACAAGCGGAGAGTTCATTTGAACCTTCCAC-3' |
|                                  | Reverse: 5'-GTTGCAAAGGCGAGAGCCATTTGAACCTTCCAC-3' |
| Ile331Asn                         | Forwards: 5'-GTGGAATTTTAGCTCTGCTGTGCCCTGAC-3' |
|                                  | Reverse: 5'-GGCAAATTTTAGCTCTGCTGTGCCCTGAC-3' |
| Asn333Ser                         | Forward: 5'-GCAGGAGCTGTGGAGCTGCCTGCTGAC-3' |
|                                  | Reverse: 5'-CCACGAGCTGTGGAGCTGCCTGCTGAC-3' |
| Cys277Ala                         | Forward: 5'-GTCAAGTCTGCGGAGCAGCGCTGAC-3' |
|                                  | Reverse: 5'-GGCAGGAGCAGCGCTGAC-3' |

TG2, transglutaminase 2; Met, methionine; Arg, arginine; Ile, isoleucine; Asn, asparagine; Ser, serine; Cys, cysteine; Ala, alanine.
Transamidation activity measurement

The Transglutaminase Assay Kit (Sigma) was used, according to the manufacturer’s instructions, to evaluate the transamidation activity of WT- and mutant TG2. TG2 protein samples used in the assay were purified by Myc immunoprecipitation (IP) from the cell lysates prepared from INS-1E cells transfected with WT- or mutant TG2 (Brymora et al. 2001).

In situ transamidation activity assay

INS-1E cells were cultured in 60 mm tissue culture plates at 60% confluency. They were then transfected with vectors expressing Myc-tagged WT- and mutant TG2 and further cultured for 48 h. Cells were pre-incubated for 1 h with 1 mM BPNH2 in standard culture medium (Antonyak et al. 2006). They were then rinsed in PBS and sensitized to glucose for 30 min in glucose-free standard medium. Cells were rinsed again in PBS, and incubated in medium containing either 3.3 or 16.7 mM glucose for 30 min. They were then lysed and the supernatant was collected for further analysis by western blot.

Insulin secretion assays

INS-1E cells were cultured and transfected with various TG2 constructs as described above. After 48 h post-transfection, cells were rinsed with PBS and sensitized to glucose for 30 min in glucose-free KRB buffer solution. Cells were rinsed again with PBS, and incubated with KRB buffer containing either 3.3 or 16.7 mM glucose for 30 min. KRB buffer was collected and analyzed for insulin content with the Ultra Sensitive Rat Insulin ELISA kit, according to the manufacturer’s instructions. Lysates of cells were collected and total protein content was determined. The insulin content of KRB buffer was determined by the Bradford assay (BioRad). The collected samples were measured for insulin content as described above.

Fluorescence microscopy

INS-1E cells were grown on cell culture slides (BD Biosciences, Mississauga, ON, Canada) at 60% confluency and transfected with various TG2 constructs. At 48 h post-transfection, cells were washed with PBST (PBS containing 0.05% Tween 20) and fixed with 10% formalin for 20 min at room temperature. After washing with PBST (2×5 min), cells were blocked with 1% BSA for 2 h at room temperature. Subsequently, the cells were incubated with an anti-Myc antibody (1:200 in 1% BSA) for 2 h at room temperature or overnight at 4 °C. The cells were washed three times with PBST, and incubated for 1 h at room temperature in a solution containing anti-rabbit Alexa Fluor 488 (1:300) in 1% BSA. The cells were then washed with PBST, mounted, and observed under a fluorescence microscope (Ande & Mishra 2009).

In-gel digestion of proteins and mass spectrometry

Coomassie Blue-stained bands (matching serotonylated bands on the overlay) were excised from the gel and cut into 1 mm3 cubes. In-gel trypsin digestion was performed as described previously (Mishra et al. 2007a,b). In brief, gel pieces were washed in 100 mM NH4HCO3 for 10 min, centrifuged, and the supernatant was discarded. Next, they were washed in 40% acetonitrile (ACN) in 100 mM NH4HCO3 for 10 min, and subsequently in ACN 5X gel volume for 5 min. These washing steps were repeated until all visible dye in the gel disappeared. The pieces were vacuum-dried briefly, then bathed in 3X gel volume of 10 mM dithiothreitol in 100 mM NH4HCO3 for 45 min at 55 °C, centrifuged, and the liquid was discarded. The difference between the volume of the liquid added and discarded was the volume of trypsin used for in-gel digestion. Then, 5 ng/μl of trypsin in 50 mM NH4HCO3 containing 5 mM CaCl2 were added to the gel fragments and incubated at 37 °C.
overnight. Peptides were extracted through liquid collection using 0.01% trifluoroacetic acid in 50% ACN and absolute CAN, and processed for mass spectrometry (Mishra et al. 2007a,b, Fofana et al. 2010).

**ATP/GTP-binding assays**

Cell culture and transfection were carried out as described above. At 48 h post-transfection, cells were rinsed in PBS and sensitized to glucose for 30 min in glucose-free standard medium. The cells were rinsed again in PBS and incubated in medium containing either 3.3 or 16.7 mM glucose for 7 and 30 min. After lysis, the supernatant was collected and 100 μg of lysates (total protein) were incubated with 20 μl of either GTP-agarose resin (50% (v/v) slurry in 10 mM Tris/300 mM NaCl/1 mM EDTA, pH 8.0) or ATP-agarose resin diluted in kinase buffer (50 mM Tris–HCl, pH 7.5, 10 mM MgCl) to a total volume of 300 μl for 2 h at 4 °C. The resin was subjected to five cycles of washing and centrifugation using ice-cold TBST before the agarose beads were resuspended in 50 mM Tris–HCl buffer (pH 7.5). The pulled-down protein was analyzed by western blot utilizing an anti-Myc antibody to determine the quantity of Myc-TG2 bound to the ATP/GTP-agarose beads.

**MTT assay**

In living cells, yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is reduced to purple formazan by mitochondrial reductases. INS-1E cells were cultured in 96-well plates at 60% confluency, transfected with constructs, and were incubated for 48 h. The culture media were replaced with 16.7 mM glucose/KRB buffer containing 5 mM CM-H2DCFDA and the cells were incubated at 37 °C for 1 h. KRB buffer was replaced with PBS after washing, to remove extracellular dye. Fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 505 nm using the FLUOstar OPTIMA plate reader and was expressed as a percentage of the positive control.

**Results**

Reduced insulin secretion from pancreatic islets isolated from TG2-null (TG2−/−) mice

TG2−/− mice have impaired glucose tolerance as a result of reduced insulin secretion from the pancreatic islets (Bernasolla et al. 2002). To confirm that the reduced insulin secretion in TG2−/− mice is a result of the loss of TG2 function in the pancreatic islets and not due to other peripheral factors, we measured GSIS from the pancreatic islets isolated from the WT and TG2−/− mice. No difference in insulin secretion was observed between the pancreatic islets from the WT and TG2−/− mice under basal glucose (3.3 mM) levels (Fig. 1A). However, in response to glucose stimulation (16.7 mM), a significant (P<0.01) reduction in insulin secretion from the pancreatic islets of TG2−/− mice was observed in comparison with WT mice (Fig. 1A). These results confirm that the lack of TG2 reduces GSIS from the pancreatic islets.

Reduced insulin secretion from INS-1E cells overexpressing Myc-TG2 mutants

Reduced insulin secretion from the pancreatic islets of TG2−/− mice confirms the importance of WT-TG2 for β-cell function (Bernasolla et al. 2002). To further establish the role of TG2 in β-cell function, we sought to demonstrate whether naturally occurring mutations also affect TG2 activity and its function on β-cell function. INS-1E cells were transfected with WT
Post-transfection, INS-1E cells were batch-challenged with glucose and insulin secretion was measured in the conditioned media. A significant increase in GSIS was found in cells transfected with WT in comparison with the vector-only control group (Fig. 1B). However, GSIS was consistently found to be lower in INS-1E cells transfected with TG2 mutants in comparison with cells transfected with WT-TG2 (Fig. 1B). This indicates that TG2 function(s) involved in insulin secretion is impaired in the naturally occurring TG2 mutants. The maximum reduction was found in Ile331Asn-TG2 (32%) followed by Met330Arg-TG2 (20%) and the least (7%) in Asn333Ser-TG2 (Fig. 1B). A reduction in GSIS (22.75%) was also found in INS-1E cells transfected with the Cys277Ala-TG2 mutant lacking transamidation function, suggesting a role for the transamidation function of TG2 in GSIS (Fig. 1B). Similar results were found with RINm5F β-cells (data not shown).

To study the effect of TG2 mutants on insulin secretory phases, insulin secretion was determined during the perifusion of INS-1E spheroidal clusters (Merglen et al. 2004). Both the first and second phases of GSIS were upregulated in spheroids overexpressing WT-TG2 in comparison with vector-transfected spheroids (Fig. 2). Both GSIS phases were reduced in spheroids expressing Ile331Asn-TG2 and the transamidation-null Cys277Ala-TG2 in comparison with WT-TG2 (Fig. 2). However, Cys277Ala-TG2-expressing INS-1E cells secreted more insulin in comparison with the vector-only control group (Fig. 2). Together, these data suggest that TG2 contributes to both phases of insulin secretion.

Cellular localization and expression of TG2 mutants

To verify that the cellular localization, expression and stability of TG2 mutants are not altered and are similar to WT-TG2, INS-1E cells were transfected with various TG2 constructs and processed for fluorescence microscopy and immunoblotting. Intracellular localization and expression levels of TG2 mutants were found to be similar to WT-TG2, suggesting that naturally occurring mutations in TG2 have no effect on cellular localization, stability and expression of TG2 (Fig. 3).

TG2 mutants have no effect on the viability of INS-1E cells

TG2 has been associated with cell viability and cell death (Fesus & Piacentini 2002). To determine whether reduced insulin secretion from INS-1E cells overexpressing TG2 mutants was due to reduced cell viability, we performed the MTT assay. No difference in cell viability and naturally occurring mutant-TG2 constructs.
was observed among the different groups, except that Ile331Asn-TG2-overexpressing cells had a non-significant reduction in cell viability in comparison with the vector and WT TG2-transfected control groups (Fig. 4A).

Reduced ROS levels in INS-1E cells overexpressing Myc-TG2 mutants

In addition to the detrimental effect of ROS on β-cell function, emerging evidence suggests that ROS signaling plays a role in GSIS (Szypowska & Burgering 2011). To investigate whether the overexpression of TG2 mutants alters intracellular ROS production, we measured ROS levels in INS-1E cells transfected with various TG2 mutants. A decrease in ROS level was observed in INS-1E cells overexpressing TG2 mutants, including the transamidation-null Cys277Ala-TG2 (Fig. 4B). These results are consistent with an earlier report showing decreased ROS production in cancer cells as a result of the downregulation of TG2 (Bae et al. 2006).

TG2 mutants have altered enzymatic activities

To determine which function of TG2 is affected in the naturally occurring TG2 mutants, INS-1E cells were transfected with WT and mutant Myc-TG2 constructs. Subsequently, Myc-TG2 was affinity purified using a Myc-IP kit and used for the measurement of TG2 transamidation and kinase activities by in vitro assays. A reduction in both transamidation and kinase activities was found in TG2 mutants in comparison with the WT control (Fig. 5). A maximum reduction in

Figure 2 Effect of WT and mutant TG2 overexpression on GSIS from spheroidal clusters composed of INS-1E cells. (A) INS-1E spheroids expressing WT and mutant TG2 were perfused at 0.3 ml/min with basal 3.3 mM glucose prior to stimulation with 16.7 mM glucose. Data points show insulin released expressed as mean ± S.E.M. ng/ml per 500 spheroids (n = 3). (B) Representative photomicrographs of spheroidal clusters of INS-1E cells used for the perfusion experiments.

Figure 3 Expression patterns of TG2 and TG2 mutants in INS-1E cells. INS-1E cells were transfected with various Myc-TG2 constructs at 60% confluency. At 48 h post-transfection, the cells were processed for fluorescence microscopy and immunoblotting. (A) For fluorescence microscopy, the cells grown in chambered slides were first incubated with a rabbit anti-Myc primary antibody (1:200 in 1% BSA) and then with an Alexa Fluor 488-conjugated anti-rabbit secondary antibody (1:300 in 1% BSA). After mounting, the cells were visualized by fluorescence microscopy. WT-TG2-transfected cells without primary antibody exposure were used as a negative control. (B) For immunoblot analysis, the cells were grown in 60 mm culture discs. Equal amounts of proteins (30 μg) were separated by SDS–PAGE and transferred onto nitrocellulose membranes. The membranes were sequentially incubated with a rabbit anti-Myc primary antibody (1:200) and then with a HRP-conjugated secondary antibody (1:3000) as described in the Materials and methods section, and visualized by enhanced chemiluminescence. Empty vector-transfected cells were included as a negative control and β-actin blot as a loading control.
TG2 transamidation activity was observed in Asn333Ser-TG2 (P < 0.01) followed by Ile331Asn-TG2 (P < 0.05) and the least in Met330Arg-TG2 (Fig. 5A). In addition, we examined the in situ transamidation activity of TG2 mutants in INS-E1 cells using biotinylated BPNH 2 as an amine substrate. A similar pattern of transamidation activity in TG2 mutants was found as that of the in vitro transamidation assay, especially in the lower half of the blots where the transamidated protein bands were relatively distinct from each other (Fig. 5B). In the case of kinase activity, a reduction in the range of 15–23% was found in all TG2 mutants including transamidation activity-dead mutant-TG2 (Fig. 5C). However, no difference in kinase activity was observed when the assay was performed at the 7-min time point in response to glucose stimulation (Fig. 5C). Collectively, these data suggest that the naturally occurring TG2 mutants have impaired transamidation and kinase activities. However, the effect on transamidation activity was found to be more pronounced than the effect on kinase activity.

Naturally occurring mutations in TG2 differentially affect GTP-binding function

To determine the effect of the naturally occurring TG2 mutations on its GTP-binding function, cell lysates prepared from INS-1E cells transfected with various Myc-TG2 constructs were processed for the pull-down assay using GTP-agarose affinity resin. GTP-agarose resin comprises GTP attached to the agarose beads via its γ-phosphate and is resistant to phosphatases present in crude cell/tissue extracts (Iismaa et al. 1997). GTP resin-bound TG2 was analyzed by immunoblotting using an anti-Myc antibody followed by densitometric analysis. Under the basal glucose concentration (3.3 mM), WT-TG2 was found to have a low GTP-binding ability, whereas Ile331Asn-TG2 was unable to bind GTP and Met330Arg had a very weak GTP-binding ability (Fig. 6A and B). Surprisingly, Asn333Ser-TG2 was found to have elevated GTP-binding ability (Fig. 6A and B). Most importantly, the GTP-binding ability of WT- and Met330Arg-TG2 was found to be increased and that of Asn333Ser-TG2 was decreased in response to glucose stimulation (Fig. 6A and B). GTP binding to Ile331Asn-TG2 was found to be low under both conditions (Fig. 6A and B). A similar binding pattern was found with ATP for Ile331Asn- and Asn333Ser-TG2 (Fig. 6A and B). However, unlike GTP binding, WT- and Met330Arg-TG2 were found to have maximum ATP-binding ability (Fig. 6A and B). Furthermore, no apparent change in ATP binding was observed under the basal and high glucose concentrations (Fig. 6A and B). Similar to kinase activity, no difference in the GTP-binding ability of TG2 was observed in response to glucose stimulation when the assay was performed at the 7-min time point (Fig. 6C). Thus, the GTP-binding function was found to be increased in WT-TG2 by glucose stimulation only at the 30-min time point and its loss more closely correlated with significantly reduced insulin secretion from INS-1E cells expressing Ile331Asn-TG2. Taken together, these data suggest an important role for the GTP-binding function of TG2 in GSIS from the pancreatic β-cells, which is most likely involved during the second phase of insulin secretion.

Protein serotonylation in INS-1E cells overexpressing WT- and mutant-TG2

Recently, activation of small GTPases through serotonylation by TG2 in response to glucose has been
reported to play a role in the regulation of insulin secretion from pancreatic β-cells (Paulmann et al. 2009). Our findings of reduced transamidation activity in TG2 mutants prompted us to examine protein serotonylation in INS-1E cells expressing various TG2 constructs. The overexpression of WT-TG2 was found to be sufficient to upregulate protein serotonylation in β-cells even under the basal glucose concentration in comparison with the vector-only control group (Fig. 7A). On the other hand, the overexpression of Cys277Ala-TG2 resulted in the downregulation of protein serotonylation (Fig. 7A). A significant upregulation of protein serotonylation was observed in cells expressing Asn333Ser-TG2 at the basal glucose concentration (Fig. 7A). Interestingly, out of the three major serotonylated bands, two were

Figure 5 Impact of the naturally occurring mutations in TG2 on its enzymatic activities. Myc-tagged WT and mutant TG2 were affinity purified as described in the Materials and methods section. (A) Histogram showing the relative transamidation activity of WT and mutant TG2 as determined by in vitro transamidation (mean ± S.E.M., n = 6). *P < 0.05; **P < 0.01 vs WT control. (B) Western blot showing in situ transamidation activity using 5-(biotinamido)pentylamine (BPNH₂) as a substrate. Cell culture and transfection were performed as described in Fig. 1. Subsequently, INS-1E cells were pre-incubated for 1 h with 1 mM BPNH₂ in standard culture medium. The cells were rinsed with PBS, and sensitized to glucose for 30 min in glucose-free standard medium and subsequently incubated in medium containing either 3.3 or 16.7 mM glucose for 30 min. The cells were then harvested and 30 μg of proteins were analyzed by SDS–PAGE and western blot using streptavidin-HRP conjugate and ECL. (C) Autoradiographs showing the kinase activity of WT and mutant TG2 at the 7- and 30-min time points in response to glucose stimulation as determined by an in vitro kinase assay. The in vitro kinase assay was performed in kinase buffer (50 mM Tris–HCl, pH 7.5, 10 mM magnesium chloride, [γ-³²P]ATP (25 μCi/ml)) containing IGFBP3 (2 μg) in a final volume of 25 μl at 30 °C. Subsequently, the mixture was resolved on SDS–PAGE and processed for autoradiography. Representative autoradiograph of three different experiments is shown. Histograms show relative changes in kinase activity as determined by the densitometric analysis of phosphorylated IGFBP3 (mean ± S.E.M., n = 3). *P < 0.05.
downregulated in response to glucose stimulation, whereas one remained unchanged in cells expressing Asn333Ser-TG2 (Fig. 7A). In contrast, all three bands were consistently upregulated in cells overexpressing WT and Met330Arg-TG2 under the high glucose concentration. Furthermore, a unique serotonylated band appeared in response to glucose stimulation in cells expressing Ile331Asn-TG2, most likely due to proteolytic cleavage of the 72 kDa band (Fig. 7A).

Subsequently, we analyzed protein serotonylation in the pancreatic islets from the WT and TG2<sup>K<sub>K</sub></sup> mice in response to glucose stimulation. A similar band pattern of serotonylated proteins was found in both cases as in INS-1E cells; however, a difference in protein serotonylation was apparent between the WT and TG2<sup>K<sub>K</sub></sup> mice (Fig. 7B). Unexpectedly, out of the three prominently serotonylated bands, two were upregulated in the pancreatic islets from the TG2<sup>−/−</sup> mice, whereas a decrease in serotonylation was found in the 72 kDa band (Fig. 7B). This may be a result of a compensatory response through an upregulation of other members of the TG family of proteins (Porzio et al. 2007). However, the inability to compensate the serotonylation of the 72 kDa band may be associated with reduced insulin secretion in TG2<sup>K<sub>K</sub></sup> mice, which is consistent with the data obtained in INS-1E cells expressing the naturally occurring TG2 mutants, especially Ile331Asn-TG2. To reveal the identity of this uniquely serotonylated 72 kDa protein band, the band was excised from an identical Coomassie Blue-stained gel and processed for mass spectrometry. A number of GTP-binding proteins were identified (Table 2). These data are consistent with a recent report on an important role of serotonylation of GTPases in insulin secretion from β-cells.
in response to glucose stimulation from the WT and immunoblot showing protein serotonylation in the pancreatic islets. Ile331Asn-TG2 is indicated by an asterisk (*). (B) Anti-serotonin antibody (1:500).

Figure 7 Protein serotonylation in INS-1E cells overexpressing TG2 and TG2 mutants. (A) Cell culture, transfection and treatment were performed as described in Figs 1, 2 and 3. Subsequently, the cells were harvested and equal amounts of proteins were analyzed by SDS–PAGE and immunoblotting using an anti-serotonin antibody (1:500). β-Actin immunoblots are shown as a loading control. The 72 kDa serotonylated protein is shown with an arrow (→) and in the proximity of the residues involved in GTP/ATP binding (Fig. 8). In fact, the Met330, Ile331, and Asn333 mutation sites in TG2 are sandwiched between the transamidation catalytic triad and GTP/ATP binding residues in TG2 (Fig. 8).

TG2 activity is regulated by ATP, GTP, and Ca2+. Protein transamidation by TG2 is inhibited by both ATP and GTP and activated by Ca2+, whereas TG2 kinase activity is inhibited by Ca2+ and promoted by ATP (Mishra & Murphy 2004, Mishra et al. 2007a,b). As ATP and Ca2+ modulate both TG2 transamidation and kinase activities and GSIS requires the upregulation of ATP and Ca2+ in a sequential manner within β-cells (Yada 1994, Pinkas et al. 2007), both TG2 activities may potentially contribute to insulin secretion. A reduction in the transamidation activity of TG2 mutants and a consistent decrease in insulin secretion from INS-1E cells overexpressing these mutants suggest a role for transamidation activity in insulin secretion. These results are in line with earlier reports on the reduction of insulin secretion from rat β-cells treated with inhibitors of TG2 transamidation activity (Bungay et al. 1986, Driscoll et al. 1997). However, the increase in Ca2+ level that leads to insulin secretion in β-cells in response to glucose is much lower (∼150–250 nM) than the level of Ca2+ (∼150–500 μM) required for TG2 transamidation activity (Lai et al. 1997, Parkash et al. 2002). In addition, intracellular levels of GTP, which is known to inhibit transamidation activity, are many fold higher (∼100 μM) than Ca2+ levels (Siegel & Khosla 2007). It is possible that ATP/GTP binding or other changes in TG2 (e.g. phosphorylation) alter the Ca2+ sensitivity of TG2, resulting in the activation of the transamidation function. However, the relatively lower reduction in insulin secretion from cells overexpressing the transamidation activity-dead Cys277Ala-TG2 mutant and the Asn333Ser-TG2 natural mutant with the greatest loss of transamidation activity, compared with cells overexpressing the Ile331Asn-TG2 mutant, suggests that TG2 transamidation activity per se is not sufficient in this process.

We then analyzed serotonylated proteins as a specific instance of transamidation, and we found that an approximately 72 kDa serotonylated protein band was more dynamically altered especially in the pancreatic islets from the TG2−/− mice and in INS-1E cells expressing the Ile331Asn-TG2 natural mutant, which have the greatest reduction in insulin secretion. This suggests that the 72 kDa protein band may be an important target for serotonylation (transamidation) associated with insulin secretion. Analysis of the ∼72 kDa serotonylated band by mass spectrometry identified a number of Rab GTPases. It should be noted that the molecular masses of proteins identified by mass spectrometry are lower than the molecular mass of the overlay serotonylated band excised from the Coomassie Blue-stained reducing gel. This would mean that these

Discussion

In this study, we analyzed the effect of naturally occurring mutations in TG2 on its transamidation, kinase, and GTP-binding functions and their association with GSIS. Our results indicate that all three reported mutations in TG2 differentially affect TG2 biological functions. This is consistent with the location of these mutations in close proximity of the transamidation catalytic triad (Cys277, His335, and Asp358) and in the proximity of the residues involved
proteins are not only serotonylated, but also cross-linked. A unique serotonylated band that appeared only in the case of Ile331Asn-TG2 in response to glucose stimulation may be due to the perturbed crosslinking of serotonylated proteins rather than the cleavage of the 72 kDa serotonylated band. As observed for transamidation, there was no correlation between insulin secretion and serotonylation levels of the ∼72 kDa band in the vector and Cys277Ala-TG2 control groups, suggesting that protein serotonylation per se is not sufficient to explain the insulin secretory phenotype of INS-1E cells overexpressing TG2 mutants. Furthermore, our findings of the impaired GTP-binding ability and decreased insulin secretion in the case of the Asn333Ser-TG2 mutant may be due to the compensatory effect of ATP on GTP binding, which is not the case with the Ile331Asn-TG2 mutant. However, a lack of the correlation between GTP/ATP-binding ability and the reduction in insulin secretion in the case of the Asn333Ser-TG2 mutant may be due to the perturbed crosslinking of serotonylated proteins rather than the cleavage of the 72 kDa serotonylated band. As Rab GTPases regulate many steps of membrane traffic, including vesicle formation, vesicle movement along with actin and tubulin networks, and membrane fusion, it is possible that serotonylation of these cytoskeletal and vesicle membrane network proteins is involved in GSIS from β-cells.

Moreover, our results suggest that naturally occurring mutations in TG2 differently affect GTP- and ATP-binding function of TG2. Most importantly, GTP-binding ability was found to be increased in WT-TG2 in response to glucose stimulation only at 30 min (i.e. corresponding to the second phase of insulin secretion) and its loss was more closely correlated in the Ile331Asn-TG2 mutant with the greatest reduction in insulin secretion. A lack of the correlation between GTP/ATP-binding ability and the reduction in insulin secretion in the case of the Asn333Ser-TG2 mutant may be due to the compensatory effect of ATP on GTP binding, which is not the case with the Ile331Asn-TG2 mutant. However, a lack of the correlation between GTP/ATP binding and decreased insulin secretion in Met330Arg-TG2 again suggests the involvement of more than one function of TG2 in insulin secretion. Furthermore, our findings of the impaired GTP-binding function of naturally occurring 7G2 mutants are consistent with an earlier report by Murthy et al. (2002) in which the substitution of a conserved

<table>
<thead>
<tr>
<th>Uniprot/SWISSPROT or Ref Seq_peptide no.</th>
<th>Probability log(e) score</th>
<th>No. of unique peptides</th>
<th>Mr</th>
<th>Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>P48036</td>
<td>−168·2</td>
<td>18</td>
<td>35·6</td>
<td>ANXA5, annexin-A5</td>
</tr>
<tr>
<td>P55260</td>
<td>−151·5</td>
<td>11</td>
<td>35·7</td>
<td>ANXA4, annexin-A4 (36 kDa ymogen granule membrane-associated protein)</td>
</tr>
<tr>
<td>Q9Z2L0</td>
<td>−113·3</td>
<td>12</td>
<td>32·2</td>
<td>VDAC1, voltage-dependent anion channel 1</td>
</tr>
<tr>
<td>P63245</td>
<td>−80</td>
<td>9</td>
<td>35·4</td>
<td>GNBP2/1, guanine nucleotide-binding protein subunit beta-2-like 1</td>
</tr>
<tr>
<td>Q09073</td>
<td>−54·7</td>
<td>8</td>
<td>32·9</td>
<td>SLC25A5, ADP/ATP translocase 2 (solute carrier family 25)</td>
</tr>
<tr>
<td>P81115</td>
<td>−53·3</td>
<td>7</td>
<td>31·8</td>
<td>VDAC2, voltage-dependent anion channel 2</td>
</tr>
<tr>
<td>Q6NY7</td>
<td>−45·5</td>
<td>7</td>
<td>22·4</td>
<td>RAB1, Ras-related protein Rab-1A</td>
</tr>
<tr>
<td>Q05962</td>
<td>−44·4</td>
<td>3</td>
<td>32·9</td>
<td>SLC25A4, ADP/ATP translocase 1 (solute carrier family 25)</td>
</tr>
<tr>
<td>Q9R12O</td>
<td>−41·4</td>
<td>4</td>
<td>30·9</td>
<td>VDAC3, voltage-dependent anion channel 3</td>
</tr>
<tr>
<td>Q9Z2T0</td>
<td>−40·3</td>
<td>5</td>
<td>26·9</td>
<td>VAMP-associated protein B, Vesicle-associated membrane protein-associated protein B</td>
</tr>
<tr>
<td>P09527</td>
<td>−37·9</td>
<td>4</td>
<td>23·5</td>
<td>RAB7A, Ras-related protein Rab-7A</td>
</tr>
<tr>
<td>P53994</td>
<td>−29·3</td>
<td>4</td>
<td>23·5</td>
<td>RAB2A, Ras-related protein Rab-2A</td>
</tr>
<tr>
<td>NP_596909</td>
<td>−26·6</td>
<td>4</td>
<td>31·4</td>
<td>SLC25A10 (solute carrier family 25)</td>
</tr>
<tr>
<td>P10536</td>
<td>−22</td>
<td>1</td>
<td>22·2</td>
<td>RAB1B, Ras-related protein Rab-1B</td>
</tr>
<tr>
<td>Q9Z2T70</td>
<td>−21</td>
<td>2</td>
<td>27·8</td>
<td>VAMP-associated protein A, Vesicle-associated membrane protein-associated protein A</td>
</tr>
<tr>
<td>NP_0010999310</td>
<td>−14·3</td>
<td>2</td>
<td>25·2</td>
<td>RAB5C, Ras-related protein Rab-5C</td>
</tr>
<tr>
<td>P61107</td>
<td>−13·5</td>
<td>2</td>
<td>23·9</td>
<td>RAB14, Ras-related protein Rab-14</td>
</tr>
<tr>
<td>Q4KM74</td>
<td>−11·8</td>
<td>2</td>
<td>24·7</td>
<td>Vesicle-trafficcging protein SEC22b</td>
</tr>
<tr>
<td>P97700</td>
<td>−11</td>
<td>2</td>
<td>34·1</td>
<td>SLC25A11 (solute carrier family 25 member 11)</td>
</tr>
<tr>
<td>Q35509</td>
<td>−9·5</td>
<td>2</td>
<td>24·5</td>
<td>RAB11B, Ras-related protein Rab-11B</td>
</tr>
<tr>
<td>NP_001100389</td>
<td>−6·7</td>
<td>2</td>
<td>34·4</td>
<td>Actin-related protein 2/3</td>
</tr>
<tr>
<td>NP_00103405</td>
<td>−5·1</td>
<td>1</td>
<td>23·7</td>
<td>RAB5B, Ras-related protein Rab-5B</td>
</tr>
<tr>
<td>XP_343460</td>
<td>−3·2</td>
<td>1</td>
<td>23·4</td>
<td>RAB6B, Ras-related protein Rab-6B</td>
</tr>
<tr>
<td>P16036</td>
<td>−1·9</td>
<td>1</td>
<td>39·6</td>
<td>Phosphate carrier protein (solute carrier family 25 member 3)</td>
</tr>
<tr>
<td>P62747</td>
<td>−1·7</td>
<td>1</td>
<td>22·1</td>
<td>Rho-related GTP-binding protein RhoB</td>
</tr>
<tr>
<td>Q62636</td>
<td>−1·6</td>
<td>1</td>
<td>20·8</td>
<td>GTP-binding protein smg p21B</td>
</tr>
<tr>
<td>P63012</td>
<td>−1·5</td>
<td>1</td>
<td>25</td>
<td>RAB3A, Ras-related protein Rab-3A</td>
</tr>
<tr>
<td>NP_001100085</td>
<td>−1·3</td>
<td>1</td>
<td>19·5</td>
<td>Actin-related protein 2/3 complex, subunit 4, subunit 4</td>
</tr>
</tbody>
</table>

*Base −10 log of expectation that this assignment is stochastic. Low expect score ( < −3·0) corresponds to a confident identification. Bold – proteins with a log expect score > −3.
that naturally occurring mutations in TG2 been found to significantly reduce GTP binding. Biological function of TG2 is most likely due to the impairment of more than one result of naturally occurring mutations in TG2 are activated in a sequential manner during the different phases of GSIS. Reduced insulin secretion as a result of TG2 are flanked by position 332 (which is flanked between two naturally occurring mutations in TG2) has been found to significantly reduce GTP binding. In summary, the data presented here demonstrate that naturally occurring mutations in TG2 differentially affect transamidation, kinase, and G-protein functions of TG2. This would imply that transamidation, kinase, and G-protein functions of TG2 are associated with each other and regulated in a coordinated manner. Furthermore, our data indicate that various functions of TG2 are activated in a sequential manner during the different phases of GSIS. Reduced insulin secretion as a result of naturally occurring mutations in TG2 is most likely due to the impairment of more than one biological function of TG2.

### Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### Funding

This work was supported by the Manitoba Health Research Council (MHRC) and the Canadian Institutes of Health Research. S M is a recipient of the Manitoba Medical Service Foundation Career Development Award and S R A is supported by an MHRC Postdoctoral Fellowship.

### References


Back KJ, Kang SK, Damron DS & Im MJ 2001 Phospholipase C G5 is a guanine nucleotide exchanging factor for transglutaminase II (Gz1) and promotes z1B-adrenoreceptor-mediated GTP binding and intracellular calcium release. *Journal of Biological Chemistry* 276 5591–5597. (doi:10.1074/jbc.M008252200)


Gentile V, Davies PJ & Baldini A 1994 The human tissue transglutami-

nase gene maps on chromosome 20q12 by in situ fluorescence


Ghosh S, Watanabe RM, Hauser ER, Valle T, Magnuson VL, Erdos MR,
Langefeld CD, Balow J Jr, Alty DS, Kohtamaki K et al. 1999 Type 2

diabetes: evidence for linkage on chromosome 20 in 716


pnas.96.5.2198)

Iisnna SE, Chung L, Wu MJ, Teller DC, Yee VC & Graham RM 1997

The core domain of the tissue transglutaminase Gh hydrolyzes GTP

and ATP. *Biochemistry* 36 11655–11664. (doi:10.1021/bi970545c)


susceptibility locus for NIDDM is localized to human chromosome

20q. *Diabetes* 46 876–881. (doi:10.2337/diabetes.46.5.876)

Johnson JD 2007 Pancreatic beta-cell apoptosis in maturity onset


2001 A low-affinity Ca2+-dependent association of calmodulin with

the Rab3A effector domain inversely correlates with insulin exocytosis.

*Diabetes* 50 2029–2039. (doi:10.2337/diabetes.50.9.2029)

Kasai K, Ohara-Imaizumi M, Takahashi N, Mizutani S, Zhao S,

Kikut T, Kasai H, Nagamatsu S, Gomi H & Izumi T 2005

Rab27a mediates the tight docking of insulin granules onto the

plasma membrane during glucose stimulation. *Journal of Clinical


Lacy PE & Kostianovsky M 1967 Method for the isolation of intact islets

of retinoblastoma protein.

activity facilitates protein kinase A induced phosphorylation


Lai T-S, Bielawska A, Peoples KA, Hannun YA & Greenberg CS 1997

Sphingosylphosphocholine reduces the calcium ion requirement

for activating tissue transglutaminase. *Journal of Biological Chemistry


Lee J, Nguyen K, Mishra S & Nyomba BL 2010 Prohibitin is

expressed in pancreatic β-cells and protects against oxidative


2004 Glucose sensitivity and metabolic-secretion coupling studied

during two-year continuous culture in INS-1E insulinoma cells.


Mishra S & Murphy LJ 2004 Tissue transglutaminase has intrinsic

kinase activity: identification of transglutaminase 2 as an insulin-like

growth factor binding protein-3 kinase. *Journal of Biological Chemistry

279* 23863–23868. (doi:10.1074/jbc.M311919200)


Phosphorylation of histones by tissue transglutaminase. *Journal

of Biological Chemistry* 281 5532–5538. (doi:10.1074/jbc.M506864200)

Mishra S, Melino G & Murphy LJ 2007a Transglutaminase 2 kinase

activity facilitates protein kinase A induced phosphorylation of

retinoblastoma protein. *Journal of Biological Chemistry* 282

18108–18115. (doi:10.1074/jbc.M607413200)

Mishra S, Moulik S & Murphy LJ 2007b Prohibitin binds to C3

and enhances complement activation. *Molecular Immunology* 44


Murthy SN, Iismaa S, Begg G, Freymann DM, Graham RM & Lorand L

2002 Conserved tryptophan in the core domain of transglutaminase

is essential for catalytic activity. *PNAS* 99 2738–2742.

(doi:10.1073/pnas.052715799)

Nguyen KH, Yao XH, Moulik S, Mishra S & Nyomba BL 2011 Human

IGF binding protein-3 overexpression impairs glucose regulation

in mice via an inhibition of insulin secretion. *Endocrinology* 152

2184–2196. (doi:10.1210/en.2010-1324)

Parkash J, Chaudhry MA, Amer AS, Christakos S & Rhoten WB 2002

Intracellular calcium ion response to glucose in beta-cells

of calbindin-D28k nullmutant mice and in betaHC13 cells


(doi:10.1385/ENDO:18:3:221)

Paulmann N, Grohmann M, Voigt JP, Burt B, Vosinckel J, Bader M,

Skelin M, Jesek M, Fink H, Rupnik M et al. 2009 Intracellular

serotonin modulates insulin secretion from pancreatic β-cells


journal.pbio.1000229)

Pinks DM, Strop P, Brunner AT & Khosla C 2007 Transglutaminase 2

undergoes a large conformational change upon activation.

*PLoS Biology* 5 e237. (doi:10.1371/journal.pbio.0050527)

Pozorio O, Massa O, Cunsolo V, Colombo C, Malaponti M, Bertuzzi F,

Hansen T, Johansen A, Pedersen O, Meschi F et al. 2007 Missense

mutations in the TG2 gene encoding transglutaminase 2 are found

in patients with early-onset type 2 diabetes. *Human Mutation* 28

1150. (doi:10.1002/humu.9511)

Siegel M & Khosla C 2007 Transglutaminase 2 inhibitors and their

therapeutic role in disease states. *Pharmacology & Therapeutics* 115

232–245. (doi:10.1016/j.pharmthera.2007.05.003)

Szypowska AA & Burgering BM 2011 The peroxide dilemma: opposing

and mediating insulin action. *Antioxidants & Redox Signaling* 15


In Frontiers of insulin secretion and pancreatic B cell research.


Zouali H, Hani EH, Philippi A, Vionnet N, Beckmann JS, Demenais F

& Froguel P 1997 A susceptibility locus for early-onset non-insulin

dependent (type 2) diabetes mellitus maps to chromosome 20q,

proximal to the phosphoenolpyruvate carboxykinase gene. *Human


Received in final form 29 February 2012
Accepted 6 March 2012
Made available online as an Accepted Preprint 6 March 2012